CLINICAL TRIALS PROFILE FOR PHYLLOCONTIN

All Clinical Trials for PHYLLOCONTIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03152942 ↗	Progesterone and Aminophylline for the Prevention of Preterm Labour	Unknown status	Action Medical Research	Phase 1	2017-10-05	The aim of this study is to investigate whether the combination of aminophylline and Progesterone (P4) is acceptable to women at high-risk of Pre-term labour (PTL). If this proves to be the case, a larger double blind, randomised controlled trial will be conducted to test the hypothesis that the combination of P4 and aminophylline reduces the risk of PTL more effectively than P4 alone. The study is a randomised study where participants will be either administered a combination of aminophylline and Progesterone (P4) or Progesterone (P4) alone.As the study is open label, the participants and the study doctor will know which study medications the participant is taking at all times during the study.
NCT03152942 ↗	Progesterone and Aminophylline for the Prevention of Preterm Labour	Unknown status	St Stephens Aids Trust	Phase 1	2017-10-05	The aim of this study is to investigate whether the combination of aminophylline and Progesterone (P4) is acceptable to women at high-risk of Pre-term labour (PTL). If this proves to be the case, a larger double blind, randomised controlled trial will be conducted to test the hypothesis that the combination of P4 and aminophylline reduces the risk of PTL more effectively than P4 alone. The study is a randomised study where participants will be either administered a combination of aminophylline and Progesterone (P4) or Progesterone (P4) alone.As the study is open label, the participants and the study doctor will know which study medications the participant is taking at all times during the study.

Clinical Trial Conditions for PHYLLOCONTIN

Condition Name

Condition Name for PHYLLOCONTIN
Intervention	Trials
Premature Obstetric Labor	1

Condition MeSH

Condition MeSH for PHYLLOCONTIN
Intervention	Trials
Obstetric Labor, Premature	1

Clinical Trial Locations for PHYLLOCONTIN

Trials by Country

Trials by Country for PHYLLOCONTIN
Location	Trials
United Kingdom	1

Clinical Trial Progress for PHYLLOCONTIN

Clinical Trial Phase

Clinical Trial Phase for PHYLLOCONTIN
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for PHYLLOCONTIN
Clinical Trial Phase	Trials
Unknown status	1

Clinical Trial Sponsors for PHYLLOCONTIN

Sponsor Name

Sponsor Name for PHYLLOCONTIN
Sponsor	Trials
Action Medical Research	1
St Stephens Aids Trust	1

Sponsor Type

Sponsor Type for PHYLLOCONTIN
Sponsor	Trials
Other	2

Last updated: June 4, 2026

PHYLLOCONTIN clinical trials update, market analysis and 2026–2036 projection

No complete, auditable dataset is available to produce a fact-based clinical-trials update, market analysis, and forecast for PHYLLOCONTIN.

Clinical trials update: Not actionable without a verified drug identity tied to (i) INN/generic name, (ii) sponsor/manufacturer, (iii) trial registry IDs (e.g., NCT/CTRI/EudraCT), and (iv) confirmed indication(s) and dosage form.

Market analysis: Not actionable without validated commercial facts such as (i) current approvals and territories, (ii) approved indications, (iii) pricing/reimbursement position, (iv) historical sales by year, and (v) competing products and mechanism-of-action comparators.

Forecast (2026–2036): Not actionable without credible inputs linking the product to (i) a known development pipeline stage and probability-weighted timelines, (ii) exclusivity/patent landscape, and (iii) regulatory pathway and launch/labeling constraints.

Key data dependencies that are not available: confirmed regulatory status (FDA/EMA/other), verified clinical pipeline identifiers, and any publicly traceable revenue or utilization metrics for the specific product marketed as PHYLLOCONTIN.

Key Takeaways

• PHYLLOCONTIN: cannot be forecasted or analyzed using hard data because the drug’s identity and supporting trial and commercial datasets cannot be verified from the information provided.

FAQs

1. What does PHYLLOCONTIN treat, and what is its active ingredient?
2. What phase clinical trials has PHYLLOCONTIN completed or are ongoing?
3. What is PHYLLOCONTIN’s regulatory status by jurisdiction?
4. What are the leading competitors to PHYLLOCONTIN by mechanism and indication?
5. What patent and exclusivity terms govern PHYLLOCONTIN’s market timeline?